Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > This drop has no reason

<< Previous

Bullboard Posts

Next >>

Comment by Davidtepperss62on Jul 21, 2020 8:32pm

145 Views

Post# 31299330

RE:This drop has no reason

The brokerage houses Canaccord and Anonyme did the same thing on the PAS stock, which went from 0.27 ¢ to 0.45 ¢ and fell to 0.22 ¢ to go up a little today to 0.23 ¢ and 0.24 ¢. Can see very well that these two control and manipulate all the other brokerage houses, so they have to do like them and follow their aggressive movements.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity